Low-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia: a systematic review and meta-analysis

The recommended standard treatment for Pneumocystis jirovecii pneumonia (PJP) is high-dose trimethoprim-sulfamethoxazole (TMP-SMX) (15-20 mg/kg/d TMP). However, the standard regimen may cause a high incidence of dose-related adverse events (AEs). Therefore, we aimed to conduct a systematic review an...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2024-11, Vol.15, p.1422490
Main Authors: Huang, Hui-Bin, Zhu, Yi-Bing, Yu, Da-Xing
Format: Article
Language:English
Subjects:
adverse event
meta-analysis
mortality
Pharmacology
Pneumocystis jirovecii pneumonia
trimethoprim-sulfamethoxazole
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recommended standard treatment for Pneumocystis jirovecii pneumonia (PJP) is high-dose trimethoprim-sulfamethoxazole (TMP-SMX) (15-20 mg/kg/d TMP). However, the standard regimen may cause a high incidence of dose-related adverse events (AEs). Therefore, we aimed to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of low-dose TMP-SMX regimens (
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2024.1422490